ArticleFrontiers in oncology2026
Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis and
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a novel prognostic and for osteosarcoma patients utilizing multiple organelle related genes.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Currently, identifying new therapeutic targets in clinical practice is crucial for improving the treatment of osteosarcoma. The abnormal expression of calcium/calmodulin-dependent serine protein kinase (CASK) plays an important role in the tumorigenesis of many cancers; however, the role of CASK in the potential therapeutic value of osteosarcoma has not been reported. Methods: The Gene Expression Omnibus (GEO) database was used to analyze the expression levels of CASK in osteosarcoma patients. Cell experiments validated the role of CASK in osteosarcoma cells and revealed the potential mechanism of action of CASK from three aspects: immunity, pathogenic gene expression, and protein interaction. Results: The results showed that CASK was significantly upregulated in osteosarcoma samples. Inhibiting the expression of CASK can significantly promote cell apoptosis and inhibit the cycle progression of osteosarcoma cells. The high expression of CASK is mainly enriched in the immune system process, the JAK/STAT signaling pathway. There is a significant positive correlation between CASK and Macrophages_M2. Changes in CASK expression levels may activate the JAK/STAT signaling pathway by affecting the immunity of Macrophages_M2, thereby regulating apoptosis and cell cycle progression in osteosarcoma cells. Discussion: In conclusion, CASK may be a potential therapeutic target for osteosarcoma patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.